Day One Biopharmaceuticals Stock Forum

$Day One Biopharmaceuticals(DAWN.US)$
$DAWN received a priority review with a PDUFA on April, 30, 2024 based on FIREFLY-1 Phase II readout. In the meantime, $DAWN was awarded Priority Review Voucher(PRV) upon approval. It is reported to have a sell-price ranging from 67M to 350M, a huge value addition upon approval.
Tovorafenib is the candidate under evaluation. It is a type II RAF inhibitor, targeting both mutation and fusion BRAF alterations. This pan-RAF inhibitor is superior to...

$SPDR S&P Biotech ETF(XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

$Day One Biopharmaceuticals(DAWN.US)$ Day One Announces FDA Acceptance Of NDA And Priority Review For Tovorafenib In Relapsed Or Progressive Pediatric Low-Grade Glioma